HomeSGX-LISTED COMPANIESmm2 Asia: FY2025 Financial Review and Future Strategy

mm2 Asia: FY2025 Financial Review and Future Strategy

Published on

spot_img

mm2 Asia LTD experienced a demanding financial year, reporting an overall net loss influenced by substantial impairment provisions and losses from associated companies. While the Content business demonstrated resilience, the Concert and Event segment encountered difficulties due to fewer projects and market shifts. The Cinema business faced considerable operational challenges, leading to strategic re-evaluation. The Group is now focused on core business growth, new ventures, and portfolio optimization for future viability.

• Discover how the Group’s established content business navigated a demanding period, maintaining its foundational strength

• Uncover the profound challenges encountered by key segments like cinema and live events, necessitating strategic re-evaluation

• Explore the forward-looking strategy that includes embracing innovative technologies and optimizing the corporate portfolio for agility

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...